This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Israelsen, M. et al. Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol. Hepatol. https://doi.org/10.1016/S2468-1253(23)00010-9 (2023)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hindson, J. Rifaximin-α for ALD: phase II results. Nat Rev Gastroenterol Hepatol 20, 269 (2023). https://doi.org/10.1038/s41575-023-00778-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-023-00778-z